Real-world prevalence of potential drug-drug interactions involving oral antineoplastic agents: a population-based study

Kim, Sung Hwan; Suh, Young Ger; Ah, Young‐Mi; Jun, Kwang‐Hee; Lee, Ju‐Yeun

doi:10.1007/s00520-019-05204-2

Cited by 13 publications

(15 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Medication errors within the comedication are an additional risk for the vulnerable patients with cancer and should not be neglected. As expected, polymedication is a risk factor for medication errors, which is in concordance with previous studies that investigated drug‐drug interactions in oncology outpatients treated with oral antitumor agents (e.g., endocrine, targeted, or traditional agents 9,15,32 ).…”

Section: Discussionsupporting

confidence: 90%

“…A systematic review on drug‐drug interactions between oral antineoplastic agents and the comedication emphasized the high risk of drug‐drug interactions and stated that published data from clinical practice is rare 33 . The prevalence and types of our results are difficult to compare with previous analyses due to different methodology (e.g., only single oral antitumor agents investigated, 34 lack of investigation of drug‐drug interactions within the co‐medication, 32,35 lack of investigation of drug‐food interactions, 15 or diverging setting 36 ). Clinical decision support systems (CDSS) focusing on drug‐drug interactions only cover a limited number of all medication errors.…”

Section: Discussionmentioning

confidence: 87%

See 1 more Smart Citation

Medication Errors During Treatment with New Oral Anticancer Agents: Consequences for Clinical Practice Based on the AMBORA Study

Schlichtig

Dürr

Dörje

et al. 2021

Clin Pharma and Therapeutics

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 90%

Section: Discussionmentioning

confidence: 87%

Medication Errors During Treatment with New Oral Anticancer Agents: Consequences for Clinical Practice Based on the AMBORA Study

Schlichtig

Dürr

Dörje

et al. 2021

Clin Pharma and Therapeutics

View full text Add to dashboard Cite

show abstract

“…The drugs involved can be prescription-only medicines or over-the-counter medicines. DDIs can be classified as pharmacokinetic or pharmacodynamic in nature [ 5 , 6 ], with pharmacokinetic DDIs being the commonest [ 7 ]. A systemic review and meta-analysis approximated that 1/10 hospitalized patients are exposed to cs-DDIs [ 2 ], 20–40% [ 5 ].…”

Section: Introductionmentioning

confidence: 99%

Frequency, severity, and factors associated with clinically significant drug-drug interactions among patients with cancer attending Mbarara Regional Referral Hospital Cancer Unit, Uganda

et al. 2022

View full text Add to dashboard Cite

Background Cancer is a major public health problem with pharmacotherapy being the cornerstone of its management. Cancer patients receive multiple drugs concurrently risking Drug-Drug Interactions (DDIs). DDIs, though avoidable, can significantly contribute to morbidity, mortality, and increased healthcare costs in this population of patients. Currently, there is no published study from Uganda on clinically significant DDIs (cs-DDIs) among cancer patients. This study identifies frequency, severity, and factors associated with cs-DDIs at Mbarara Regional Referral Hospital Cancer Unit (MRRHCU). Method A cross-sectional study was conducted among 300 cancer patients receiving chemotherapy from a tertiary care hospital in western Uganda from January–February 2022. A questionnaire and data collection form were used to collect patient data. Lexicomp® Drug interaction software was used to screen the patient drug information for DDIs and assess their severity. Predictors of DDIs were identified using logistic regression using SPSS (Statistical Package for Social Sciences). Result Three hundred participants were enrolled with a mean age of 48 ± 23.3 years. One hundred eighty-one patients experienced 495 cs-DDIs; with a mean of 1.7 ± 2.2. The prevalence of cs-DDI was 60.3% (55.0-66.0% at 95% CI). Digestive organ neoplasms were the most commonly (80, 26.7%) diagnosed category, and ‘plant alkaloids and other natural products were the most frequently (143, 47.7%) used chemotherapeutic drug classes. About three-quarters of cs-DDIs were rated as category C risk (367, 74.1%) whereas over two-thirds (355, 71.7%) were moderate in severity.. Being female (aOR = 2.43 [1.23–4.48 at 95% CI]; P-value = 0.011) and use of ≥ 6 drugs concurrently (aOR = 18.82 [9.58–36.95 at 95% CI]; P-value < 0.001)) were significantly associated with cs-DDIs. Conclusion More than half of the participants experienced at-least one cs-DDI which is generally higher than what was reported in high-income settings. About three-quarters were category C and moderate in severity, and require enhanced monitoring for safety and treatment outcome. Being female and using ≥ 6 drugs were significantly associated with cs-DDIs.

show abstract

“…However, India reported that 88.9% had at least one DDI [ 27 ], and in Pakistan, it was 92% [ 28 ], and the findings in both studies are similar to our analysis. In a study conducted in Korea specifically on oral antineoplastic agents, the prevalence was highest among the targeted agents (63.2%) followed by traditional agents (21.2%) and endocrine agents (19.3%) [ 29 ]. Furthermore, previous studies in Palestine also reported potentially high percentages of DDIs among different populations, such as hemodialysis patients (89.1%) [ 18 ] and cardiovascular patients (94%); [ 19 ].…”

Section: Discussionmentioning

confidence: 99%

A comprehensive evaluation of potentially significant drug-drug, drug-herb, and drug-food interactions among cancer patients receiving anticancer drugs

et al. 2022

View full text Add to dashboard Cite

Introduction During the cancer treatment path, cancer patients use numerous drugs, including anticancer, supportive, and other prescribed medications, along with herbs and certain products. This puts them at risk of significant drug interactions (DIs). This study describes DIs in cancer patients and their prevalence and predictors. Methods A cross-sectional study design was used to achieve the study objectives. The study was carried out in two centers in the northern West Bank, Palestine. The Lexicomp® Drug Interactions tool (Lexi-Comp, Hudson OH, USA) was applied to check the potential DIs. In addition, the Statistical Package for the Social Sciences (SPSS) was used to show the results and find the associations. Results The final analysis included 327 patients. Most of the participants were older than 50 years (61.2%), female (68.5%), and had a solid tumor (74.6%). The total number of potential DIs was 1753, including 1510 drug-drug interactions (DDIs), 24 drug-herb interactions, and 219 drug-food interactions. Importantly, the prevalence of DDIs was 88.1%. In multivariate analysis, the number of potential DDIs significantly decreased with the duration of treatment (p = 0.007), while it increased with the number of comorbidities (p < 0.001) and the number of drugs used (p < 0.001). Conclusions We found a high prevalence of DIs among cancer patients. This required health care providers to develop a comprehensive protocol to monitor and evaluate DIs by improving doctor-pharmacist communication and supporting the role of clinical pharmacists.

show abstract

Real-world prevalence of potential drug-drug interactions involving oral antineoplastic agents: a population-based study

Cited by 13 publications

References 20 publications

Medication Errors During Treatment with New Oral Anticancer Agents: Consequences for Clinical Practice Based on the AMBORA Study

Medication Errors During Treatment with New Oral Anticancer Agents: Consequences for Clinical Practice Based on the AMBORA Study

Frequency, severity, and factors associated with clinically significant drug-drug interactions among patients with cancer attending Mbarara Regional Referral Hospital Cancer Unit, Uganda

A comprehensive evaluation of potentially significant drug-drug, drug-herb, and drug-food interactions among cancer patients receiving anticancer drugs

Contact Info

Product

Resources

About